Clinical trial
A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa…
NCT03528551 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT03528551 |
|---|---|
| Title | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A |
| Official title | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A |
| Acronym | pathfinder8 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A |
| Intervention type | Drug |
| Interventions | Turoctocog alfa pegol |
| Enrollment | 160 |
| Start date | Apr 30, 2018 |
| Primary completion | Dec 3, 2020 |
| Completion | Dec 3, 2020 |
| First posted | May 18, 2018 |
| Last update posted | Dec 22, 2022 |
| Countries | Australia, Brazil, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan and 14 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: